BC Extra | Jan 28, 2020
Company News

Bourla chooses BD over buybacks in 2020

CEO Albert Bourla outlined his vision for the new innovative business that will emerge from Pfizer after the spin-off of Upjohn, saying that the company would invest in business development and pipeline growth rather than...
BC Extra | Aug 16, 2019
Company News

Rinvoq approval bolsters AbbVie's autoimmune portfolio

With Humira adalimumab set to face increasing biosimilar competition internationally this year, AbbVie has notched its second U.S. regulatory win for a successor to its primary revenue driver with FDA’s approval Rinvoq upadacitinib on Friday...
BC Extra | Jul 26, 2019
Company News

July 26 Company Quick Takes: Lexicon hit by Phase III miss, scuttled deal; plus Xeljanz, Shield, Galapagos, Amarin and more

Sanofi canceling diabetes deal following Phase III misses Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) dropped $2.79 (49%) to $2.90 in after-hours trading Friday after Sanofi (Euronext:SAN; NASDAQ:SNY) said it would terminate the partners’ collaboration on Zynquista sotagliflozin...
BC Extra | Jul 3, 2019
Clinical News

July 3 Clinical Quick Takes: GSK starts Phase III otilimab RA program; plus Unum, Xofluza and more

Otilimab triggers milestone for MorphoSys MorphoSys AG (Xetra:MOR; NASDAQ:MOR) will receive a milestone payment of €22 million ($27.7 million) after partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) started the Phase III ContRAst program of otilimab to treat...
BC Week In Review | Feb 22, 2019
Clinical News

Pfizer reports increase in lung clots, death with high-dose Xeljanz in postmarket study

Pfizer Inc. (NYSE:PFE) disclosed an increase in pulmonary embolisms and deaths among rheumatoid arthritis patients receiving the twice-daily 10 mg dose of Xeljanz tofacitinib in the A3921133 postmarketing CV safety trial. The pharma said Feb....
BC Extra | Feb 20, 2019
Clinical News

Pfizer reports increase in lung clots, death with high-dose Xeljanz in postmarket study

Pfizer Inc. (NYSE:PFE) disclosed an increase in pulmonary embolisms and deaths among rheumatoid arthritis patients receiving the twice-daily 10 mg dose of Xeljanz tofacitinib in the A3921133 postmarketing CV safety trial. The pharma said Tuesday...
BC Extra | Oct 1, 2018
Company News

Pfizer COO Bourla to succeed Read as CEO

Pfizer Inc. (NYSE:PFE) named an insider, COO Albert Bourla, to succeed Ian Read as CEO on Jan. 1. During Read’s eight-year tenure, he reshaped Pfizer into a slimmer, three-part organization and helped it navigate key...
BC Week In Review | Aug 3, 2018
Company News

Pfizer's Read expecting rebate elimination

Chairman and CEO of Pfizer Inc. (NYSE:PFE) Ian Read expects President Donald Trump and the administration to eliminate rebates, the exec said on Pfizer's 2Q18 earnings call. Read said the current rebate structure is not...
BC Extra | Jul 31, 2018
Company News

Pfizer's Read expecting rebate elimination

Chairman and CEO of Pfizer Inc. (NYSE:PFE) Ian Read expects President Donald Trump and the administration to eliminate rebates, the exec said Tuesday on Pfizer's 2Q18 earnings call. Read said the current rebate structure is...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with...
Items per page:
1 - 10 of 142